Evidence item

The primary randomized trial reports no improvement in symptom score, six-minute walk distance or secondary endpoints with pooled mitiperstat doses versus placebo. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 19698

Source: Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial · locator {} · excerpt hash sha256:823038b55495090f586780b935a58f469c778f680bc74611fef34879c23b402c

In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS (placebo-corrected difference in mean change from baseline, –1.4 points (95% confidence interval (CI) –3.9, 1.2; P = 0.29), 6MWD (3.8 m (95% CI –3.1, 10.8)); P = 0.28) or any secondary endpoint.